Study on Adaptive Immunotherapy with VEGFR-TKI for Patients with Advanced Kidney Cancer

Inclusion Criteria

• Have advanced kidney cancer that cannot be surgically removed, specifically clear cell type.
• Be 18 years or older.
• Be in relatively good health, with a performance status score of 2 or less.
• Provide a tumor sample from a previous biopsy or be willing to undergo a new biopsy if needed.
• Have not received any prior treatment for metastatic clear cell kidney cancer.
• Have measurable cancer as defined by specific medical criteria.
• Have adequate blood, liver, and kidney function based on lab tests.
• Women of childbearing age must have a negative pregnancy test and agree to use effective birth control during and after the study.
• Men and women must agree to use two forms of birth control during and after the study.
• Be able to understand and agree to the study requirements.
• Patients with well-controlled Hepatitis B, Hepatitis C, or HIV are eligible.

Exclusion Criteria

• Have had major surgery within the last 4 weeks or radiation therapy within the last 2 weeks.
• Have received previous treatments for kidney cancer.
• Have severe allergies to the study medications.
• Have an immune deficiency or are taking high doses of steroids or other immune-suppressing drugs.
• Have another active cancer that has required treatment in the last year.
• Have active cancer spread to the brain or spinal cord unless stable and treated.
• Have had lung inflammation requiring steroids in the past 6 months.
• Have an active infection needing treatment.
• Have uncontrolled HIV, Hepatitis B, or Hepatitis C.
• Have significant digestive issues affecting medication absorption.
• Have a heart condition or stroke within the last 6 months.
• Have poorly controlled high blood pressure.
• Have issues with wound healing or active bleeding.